Corporate Magazine 2012 - Boehringer Ingelheim

our marketsperspectives for established marketsBOEHRINGER INGELHEIM IN THE USABoehringer Ingelheim hasbeen represented in the USAsince 1971. In 2012, the companyhad 10,855 employees(average 2012) and turnoverof EUR 5.55 billion.Boehringer Ingelheim Pharmaceuticals,Inc., headquarteredin Ridgefield, Connecticut,is the largest US subsidiary.Other sites are located in thestates Ohio, Iowa, Missouriand California. BoehringerIngelheim Roxane, Inc., basedin Columbus, Ohio, is, forexample, one of BoehringerIngelheim’s production andlaunch sites.In Fremont, California, biopharmaceuticalproducts havebeen manufactured since 2011.The Animal Health business isalso represented in the USAby three sites, St Joseph, FortDodge and Ames.fremontfort dodgest josephcolumbusamesridgefieldbedfordpetersburgdemonstration of value of brandsversus generic standards of care,medical cost savings and defined andreproducible health outcomes.• Cooperation between payers, plansand organised providers will grow inimportance. New and different groupscontinue to be formed. Diversity inthe make up and focus of thesegroups will mean that the industrywill need to be flexible in its approach.Different competencies andaccount management skills are beingdeveloped.• The traditional detailing model tophysicians is facing challenges. Payerinfluence, laws and regulations andprovider consolidation, have impactedtraditional detailing models. Newengagement models with healthcareproviders are being developed, particularlywhere representative accessis restricted.• Empowered consumers and physiciansrequire multi-channel communication,decision support and behaviourmanagement tools.ACCESS, AFFORDABILITYAND QUALITYUS healthcare reform is centredon the core issues of access, affordabilityand quality of care.Transformation in healthcare tomeet these needs is dynamic.Boehringer Ingelheim is focusedon the planning and executionof effective go-to-market and externalcollaboration strategies,adopting new business prioritiesand capturing the current andfuture business opportunities.• Personalised medicines, the approachof tailoring medicines to the individual,is no longer confined to researchlaboratories. The last decadehas seen an increasing number oftargeted therapies brought to market,improving the predictability ofoutcomes. Boehringer Ingelheimwill be entering the field of personalisedmedicines in 2013 with entryinto oncology and with the launchof afatinib.USA – fundamental reforms125